A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren’s Syndrome
Description
The study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity; Population 2 will include participants with moderate to severe subjective symptoms. This study will include 3 periods: screening (5 weeks), treatment period (48 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized to receive subcutaneous (SC) dose of HZN-1116 or placebo.
Acquired from Horizon in 2024.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites